Vivienne I. Rebel - 17 Nov 2022 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
EVP, Chief Sci. & Med. Officer
Signature
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Vivienne Rebel
Issuer symbol
BIAF
Transactions as of
17 Nov 2022
Net transactions value
$0
Form type
4
Filing time
22 Nov 2022, 15:49:39 UTC
Previous filing
22 Nov 2022
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIAF Common Stock, par value $0.007 Award $0 +7,239 +101% $0.000000 14,381 17 Nov 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Dr. Rebel of 7,239 restricted shares of the Issuer's common stock, par value $0.007 (the "Common Stock"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 603 shares of Common Stock and the last of which will be of the remaining 606 shares of Common Stock, subject to Dr. Rebel's continuous service to the Issuer through each vesting date.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Vivienne Rebel)